Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Post by lorbason Nov 03, 2020 5:11pm

132 Views

Post# 31833780

Q3 Earnings Thursday, November 12, AH; CC Friday November 13

https://cipher.investorroom.com/2020-11-03-Cipher-Pharmaceuticals-Schedules-Q3-2020-Earnings-Release-and-Conference-Call

OAKVILLE, ON, Nov. 3, 2020 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it will release its Q3 2020 financial results after the close on Thursday, November 12, 2020. The Company will hold a conference call on Friday, November 13, 2020 to discuss the results.

CONFERENCE CALL DETAILS

DATE:	Friday, November 13, 2020
TIME:	8:30 a.m ET
DIAL-IN:	(416) 764-8688 or (888) 390-0546
CONFERENCE ID:	46246305
REPLAY DIAL-IN:	1 (888) 390-0541 (Playback 246305 #)
Expires November 20, 2020
Webcast: https://produceredition.webcasts.com/starthere.jsp?ei=1397006&tp_key=a8d3b9b5c2